Cardinal Health Inc. stock (US14149Y1082): shares edge lower after recent gains on NYSE

Cardinal Health Inc. shares in the United States started the new week on a softer note, with the New York Stock Exchange-listed stock trading around USD 224 in early transactions on 06/01/2026 after closing near USD 224.44 on 05/31/2026, according to pricing data cited by ad-hoc-news.de and recent NYSE quote information. The move came after a solid advance in May that left the US healthcare distributor near the upper end of its 12-month range, keeping the focus on how the stock consolidates these gains in its home market.

Trading in Cardinal Health on the NYSE under the ticker CAH remained orderly, with prices fluctuating close to the prior close around USD 224 and only limited intraday volatility reported by US market data providers on 06/01/2026. For German investors, Cardinal Health is also accessible via secondary venues such as Tradegate, where indicative quotes on 06/01/2026 translated the US price into euro terms, offering euro-based exposure to the US healthcare distributor alongside the primary US listing.

As of: 01/06/2026

By the editorial team - specialized in equity coverage.

Cardinal Health Inc.: core business model

Cardinal Health functions as a large-scale healthcare supply and logistics specialist that generates most of its revenue from distributing branded and generic drugs as well as medical and laboratory products to hospitals, pharmacies, and other care providers.

Recent corporate actions

On 05/02/2026, Cardinal Health filed a Form 8-K with the US Securities and Exchange Commission outlining the results of its 2026 annual meeting of shareholders, where investors approved the election of directors and the appointment of the independent auditor for the current fiscal year, according to documents available on sec.gov and the company’s investor relations site. Earlier, on 02/01/2026, Cardinal Health had reported in a separate SEC filing that it entered into a new multi-year revolving credit facility, providing the US-based distributor with additional liquidity headroom and financial flexibility for working capital and general corporate purposes, as disclosed in the accompanying 8-K and related credit agreement.

What banks and research houses say about Cardinal Health Inc.

According to MarketBeat as of 05/31/2026, the consensus across 12 analysts covering Cardinal Health is a "Moderate Buy" rating with an average price target of USD 215.00, based on MarketBeat data compiled on that date and reflecting research input from several major US and global investment banks. The same MarketBeat overview on 05/31/2026 indicated that within this group of analysts there are a mix of buy, hold, and one sell recommendation, underscoring that while many institutions see upside in the US healthcare distributor relative to the current NYSE price, there is no uniform view on its valuation or risk profile.

Conclusion

The latest trading session on the New York Stock Exchange left Cardinal Health marginally below its end-of-May level, but still close to the upper part of its recent trading corridor in the United States after a period of solid gains. With a MarketBeat consensus suggesting a moderate buy rating and an average price target slightly below the current NYSE quote, investors are weighing the distributor’s execution in pharmaceuticals and medical products against the already robust share price. How Cardinal Health balances its capital allocation, maintains supply-chain reliability, and responds to competitive and regulatory pressures in US healthcare will remain key themes for the stock in the coming weeks.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.